HBIO
Price
$2.39
Change
-$0.00 (-0.00%)
Updated
Nov 7 closing price
118 days until earnings call
XRAY
Price
$17.26
Change
-$0.00 (-0.00%)
Updated
Nov 7 closing price
110 days until earnings call
Ad is loading...

HBIO vs XRAY

Header iconHBIO vs XRAY Comparison
Open Charts HBIO vs XRAYBanner chart's image
Harvard Bioscience
Price$2.39
Change-$0.00 (-0.00%)
Volume$293.79K
CapitalizationN/A
DENTSPLY SIRONA
Price$17.26
Change-$0.00 (-0.00%)
Volume$30.26M
CapitalizationN/A
View a ticker or compare two or three
HBIO vs XRAY Comparison Chart
Loading...
HBIO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
XRAY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
HBIO vs. XRAY commentary
Nov 09, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HBIO is a Hold and XRAY is a Buy.

COMPARISON
Comparison
Nov 09, 2024
Stock price -- (HBIO: $2.39 vs. XRAY: $17.26)
Brand notoriety: HBIO and XRAY are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: HBIO: 253% vs. XRAY: 1044%
Market capitalization -- HBIO: $184.01M vs. XRAY: $6.69B
HBIO [@Medical Specialties] is valued at $184.01M. XRAY’s [@Medical Specialties] market capitalization is $6.69B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $7.99B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HBIO’s FA Score shows that 1 FA rating(s) are green whileXRAY’s FA Score has 1 green FA rating(s).

  • HBIO’s FA Score: 1 green, 4 red.
  • XRAY’s FA Score: 1 green, 4 red.
According to our system of comparison, both HBIO and XRAY are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HBIO’s TA Score shows that 3 TA indicator(s) are bullish while XRAY’s TA Score has 4 bullish TA indicator(s).

  • HBIO’s TA Score: 3 bullish, 6 bearish.
  • XRAY’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, XRAY is a better buy in the short-term than HBIO.

Price Growth

HBIO (@Medical Specialties) experienced а +1.70% price change this week, while XRAY (@Medical Specialties) price change was -25.51% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +2.61%. For the same industry, the average monthly price growth was +3.41%, and the average quarterly price growth was -0.22%.

Reported Earning Dates

HBIO is expected to report earnings on Mar 06, 2025.

XRAY is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Medical Specialties (+2.61% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XRAY($6.69B) has a higher market cap than HBIO($184M). XRAY YTD gains are higher at: -50.655 vs. HBIO (-55.327). XRAY has higher annual earnings (EBITDA): 249M vs. HBIO (8.03M). XRAY has more cash in the bank: 334M vs. HBIO (4.28M). HBIO has less debt than XRAY: HBIO (42.8M) vs XRAY (2.3B). XRAY has higher revenues than HBIO: XRAY (3.97B) vs HBIO (112M).
HBIOXRAYHBIO / XRAY
Capitalization184M6.69B3%
EBITDA8.03M249M3%
Gain YTD-55.327-50.655109%
P/E RatioN/A19.23-
Revenue112M3.97B3%
Total Cash4.28M334M1%
Total Debt42.8M2.3B2%
FUNDAMENTALS RATINGS
HBIO vs XRAY: Fundamental Ratings
HBIO
XRAY
OUTLOOK RATING
1..100
42
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
4
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9391
PRICE GROWTH RATING
1..100
5961
P/E GROWTH RATING
1..100
291
SEASONALITY SCORE
1..100
5047

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XRAY's Valuation (4) in the Medical Specialties industry is significantly better than the same rating for HBIO (99) in the Biotechnology industry. This means that XRAY’s stock grew significantly faster than HBIO’s over the last 12 months.

XRAY's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as HBIO (100) in the Biotechnology industry. This means that XRAY’s stock grew similarly to HBIO’s over the last 12 months.

XRAY's SMR Rating (91) in the Medical Specialties industry is in the same range as HBIO (93) in the Biotechnology industry. This means that XRAY’s stock grew similarly to HBIO’s over the last 12 months.

HBIO's Price Growth Rating (59) in the Biotechnology industry is in the same range as XRAY (61) in the Medical Specialties industry. This means that HBIO’s stock grew similarly to XRAY’s over the last 12 months.

HBIO's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for XRAY (91) in the Medical Specialties industry. This means that HBIO’s stock grew significantly faster than XRAY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HBIOXRAY
RSI
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
67%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
52%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
N/A
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
60%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
70%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
71%
Advances
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
57%
Declines
ODDS (%)
Bearish Trend 15 days ago
80%
Bearish Trend 17 days ago
69%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
40%
Aroon
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
81%
View a ticker or compare two or three
Ad is loading...
HBIO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
XRAY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RAPAX10.520.10
+0.96%
Cohen & Steers Real Assets A
FCGCX19.490.18
+0.93%
Fidelity Advisor Global Commodity Stk C
WAUSX16.320.13
+0.80%
Wasatch US Select Investor
BKMIX10.320.04
+0.39%
BlackRock Multi-Asset Income Portfolio K
HWAAX42.72N/A
N/A
Hotchkis & Wiley Value Opps A

HBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, HBIO has been loosely correlated with CRL. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if HBIO jumps, then CRL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HBIO
1D Price
Change %
HBIO100%
-15.25%
CRL - HBIO
43%
Loosely correlated
-1.83%
CTKB - HBIO
43%
Loosely correlated
-2.43%
PACB - HBIO
42%
Loosely correlated
-7.55%
KIDS - HBIO
42%
Loosely correlated
-11.18%
FLGT - HBIO
42%
Loosely correlated
-2.91%
More

XRAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, XRAY has been loosely correlated with NVST. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if XRAY jumps, then NVST could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XRAY
1D Price
Change %
XRAY100%
-28.02%
NVST - XRAY
64%
Loosely correlated
-2.24%
KIDS - XRAY
48%
Loosely correlated
-11.18%
AZTA - XRAY
47%
Loosely correlated
-2.19%
CRL - XRAY
46%
Loosely correlated
-1.83%
HBIO - XRAY
45%
Loosely correlated
-15.25%
More